Trial site
Instituto de Educacao Pesquisa e Gestao em Saude
Rio de Janeiro, 22775-001, BrazilNot linked to an institution yet
- 11running trials
- 1closed trial
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 22 trials
- Status
- Active, not recruiting7 trials
- Recruiting3 trials
- Completed1 trial
- Enrolling by invitation1 trial
- Lead sponsor
- Pfizer3 trials
- Intellia Therapeutics2 trials
- Tolmar Inc.2 trials
- Amgen1 trial
- Eli Lilly and Company1 trial
- and 3 more
Running trials
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source
Contact: Relay Therapeutics, Inc
Active, not recruiting
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· Phase 2· Amgen· Source
Active, not recruiting
A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT06672237· Phase 3· Intellia Therapeutics· Source
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629· Phase 3· Intellia Therapeutics· Source
Contact: Trial Manager at Intellia
Enrolling by invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536· Phase 3· Tolmar Inc.· Source
Active, not recruiting
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136· Phase 2· Mirum Pharmaceuticals, Inc.· Source
Active, not recruiting
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395· Phase 3· Tolmar Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error